单克隆抗体

Monoclonal Antibodies.

作者信息

Geskin Larisa J

机构信息

Comprehensive Cutaneous Oncology Center, Department of Dermatology, Columbia University, 161 Fort Washington Avenue, 12th floor, New York, NY 10032, USA.

出版信息

Dermatol Clin. 2015 Oct;33(4):777-86. doi: 10.1016/j.det.2015.05.015.

DOI:10.1016/j.det.2015.05.015

PMID:26433849

Abstract

Use of monoclonal antibodies (mAbs) has revolutionized cancer therapy. Approaches targeting specific cellular targets on the malignant cells and in tumor microenvironment have been proved to be successful in hematologic malignancies, including cutaneous lymphomas. mAb-based therapy for cutaneous T-cell lymphoma has demonstrated high response rates and a favorable toxicity profile in clinical trials. Several antibodies and antibody-based conjugates are approved for use in clinical practice, and many more are in ongoing and planned clinical trials. In addition, these safe and effective drugs can be used as pillars for sequential therapies in a rational stepwise manner.

摘要

单克隆抗体（mAb）的使用彻底改变了癌症治疗方法。靶向恶性细胞和肿瘤微环境中特定细胞靶点的方法已被证明在血液系统恶性肿瘤（包括皮肤淋巴瘤）中是成功的。基于单克隆抗体的皮肤T细胞淋巴瘤治疗在临床试验中已显示出高缓解率和良好的毒性特征。几种抗体和基于抗体的偶联物已被批准用于临床实践，还有更多正在进行和计划中的临床试验。此外，这些安全有效的药物可以合理地逐步用作序贯治疗的支柱。